Li et al. identify deoxycholic acid as a microbiota-derived driver of breast cancer progression. Deoxycholic acid activates farnesoid X receptor signaling to induce interleukin-6 production, promoting immunosuppressive cell recruitment and establishing a metabolite-driven immune regulatory axis with therapeutic potential.